The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1040
November 20, 1998
View Complete Issue         Table of Contents 2019 
New Drugs for Rheumatoid Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
New Drugs for Rheumatoid Arthritis
November 20, 1998 (Issue: 1040)
Leflunomide (Arava - Hoechst Marion Roussel), which inhibits pyrimidine synthesis, and etanercept (Enbrel - Immunex/Wyeth-Ayerst), which blocks the action of tumor necrosis factor (TNF), have been approved by the FDA for treatment of rheumatoid ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: New Drugs for Rheumatoid Arthritis
Article code: 1040b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.